Enter to open, tab to navigate, enter to select
Dechert: Publicly-Traded Life Sciences Companies of All Sizes Remain Prime Targets of Securities Fraud Class Action Lawsuits
Practical Law Article 0-506-0654 (Approx. 2 pages)
Dechert: Publicly-Traded Life Sciences Companies of All Sizes Remain Prime Targets of Securities Fraud Class Action Lawsuits
by Dechert LLP
| Published on 31 Mar 2011 • USA (National/Federal) |
This Dechert LLP memorandum discusses a Dechert LLP survey finding that life sciences companies of all sizes remain prime targets of securities fraud class action lawsuits.